Document is current

Article History

Accepted: 28 October 2024

First Online: 8 January 2025

Declarations

:

: NSRL has received research funding from Sanofi as part of a Clinical Fellowship in Endocrinology and Diabetes, education support from Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, CSL Seqirus, Eli Lilly, Novartis and Pfizer, speaker honoraria from Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Menarini, Novartis and Sanofi, and has participated in advisory boards for Eli Lilly. RTC has nothing to declare. SJN has received research support from AstraZeneca, Amgen, Anthera, CSL Behring, Cerenis, Cyclarity, Eli Lilly, Esperion, Resverlogix, New Amsterdam Pharma, Novartis, InfraReDx and Sanofi-Regeneron and is also a consultant for Amgen, Akcea, AstraZeneca, Boehringer Ingelheim, CSL Behring, Cyclarity, Daiichi Sankyo, Eli Lilly, Esperion, Kowa, Merck, Takeda, Pfizer, Sanofi- Regeneron, Vaxxinity, CSL Seqirus, and Novo Nordisk. GD reports paid lectures from AstraZeneca, Pfizer and Amgen and provides consultancy services and has equity interest in Artrya Ltd. GFW has received honoraria for advisory boards and research grants from Amgen, Arrowhead, Esperion, Gemphire, Kowa, Novartis, Pfizer, Sanofi, Novo Nordisk and Regeneron. AJN has received research support from AstraZeneca, Amgen, Eli Lilly, Novartis and is a consultant for Amgen, AstraZeneca, Boehringer Ingelheim, CSL Sequiris, Eli Lilly, GSK, Sanofi Pasteur and Novo Nordisk.

: This article does not contain any studies with human or animal subjects performed by any of the authors.